Clinical Trial Update: Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes [Phase 2]

View source ↗

Summary

Phase II study of avelumab as second-line treatment for metastatic gastroenteropancreatic neuroendocrine carcinoma (WHO Grade 3) afteretoposide+cispaltin failur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Neuroendocrine Carcinoma, Grade 3 | Phase 2 | Status: COMPLETED